Offering healthcare solutions at consumers' fingertips? What you should know about FDA regulation of mobile medical apps
By Mary B Langowski, Rebecca Jones McKnight, Kristen E Ratcliff and So-Eun Lee
More than two years after the Food and Drug Administration (FDA) issued draft guidance on ‘mobile medical applications’, the agency recently issued its greatly anticipated final guidance. As the FDA considered comments from stakeholders during this prolonged review period, many in the industry continued to struggle with understanding the boundaries proposed by the FDA and their potential impact on businesses across the healthcare sector.
The principles outlined in the final guidance remain consistent with those described in the draft guidance. The FDA has stated that it is ‘not expanding [the FDA’s] universe’ by regulating mobile medical applications (i.e. apps), but rather applying longstanding basic tenets of medical device regulation and — at the core — requirements of the Food, Drug and Cosmetic Act (FDCA). These principles may, however, be unfamiliar to many in the technology space, particularly those who have not previously been involved with FDA-regulated devices.
In response to industry requests for clarity, FDA added a number of specific examples in the final guidance, including examples of mobile apps that would not be considered regulated devices and those that would technically be considered devices, but to which the FDA would apply enforcement discretion…
If you are registered and logged in to the site, click on the link below to read the rest of the DLA Piper briefing. If not, please register or sign in with your details below.
Sign in or Register to continue reading this article
It's quick, easy and free!
It takes just 5 minutes to register. Answer a few simple questions and once completed you’ll have instant access.Register now
Why register to The Lawyer
In-depth, expert analysis into the stories behind the headlines from our leading team of journalists.
Identify the major players and business opportunities within a particular region through our series of free, special reports.
Receive your pick of The Lawyer's daily and weekly email newsletters, tailored by practice area, region and job function.
More relevant to you
To continue providing the best analysis, insight and news across the legal market we are collecting some information about who you are, what you do and where you work to improve The Lawyer and make it more relevant to you.
News from DLA Piper
News from The Lawyer
Briefings from DLA Piper
The Australian Taxation Office released a draft ruling on the Goods and Services Tax treatment of bitcoin transactions on 20 August 2014.
DLA Piper’s ‘Life sciences: patent extension strategies and antitrust global update’ video covers global antitrust and competition issues including product hopping and reverse payment patents.
Analysis from The Lawyer
Cross-border work and political tensions are dominating this year’s entries for Finance Team of the Year at The Lawyer Awards.
Regulators are ramping up the pressure in the aftermath of recession, leaving firms to compete for compliance and restructuring work